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Transcranial direct current stimulation (tDCS) delivered in multiple sessions can reduce
symptom burden, but access of chronically ill patients to tDCS studies is constrained by
the burden of office-based tDCS administration. Expanded access to this therapy can
be accomplished through the development of interventions that allow at-home tDCS
applications.
Objective: We describe the development and initial feasibility assessment of a novel
intervention for the chronically ill that combines at-home tDCS with telehealth support.
Methods: In the developmental phase, the tDCS procedure was adjusted for easy
application by patients or their informal caregivers at home, and a tDCS protocol with
specific elements for enhanced safety and remote adherence monitoring was created.
Lay language instructional materials were written and revised based on expert feedback.
The materials were loaded onto a tablet allowing for secure video-conferencing. The
telehealth tablet was paired with an at-home tDCS device that allowed for remote dose
control via electronic codes dispensed to patients prior to each session. tDCS was
delivered in two phases: once daily on 10 consecutive days, followed by an as needed
regimen for 20 days. Initial feasibility of this tDCS-telehealth system was evaluated in
four patients with advanced chronic illness and multiple symptoms. Change in symptom
burden and patient satisfaction were assessed with the Condensed Memorial Symptom
Assessment Scale (CMSAS) and a tDCS user survey.
Results: The telehealth-tDCS protocol includes one home visit and has seven patient-
tailored elements and six elements enhancing safety monitoring. Replicable electrode
placement at home without 10–20 EEG measurement is achieved via a headband that
holds electrodes in a pre-determined position. There were no difficulties with patients’
training, protocol adherence, or tolerability. A total of 60 tDCS sessions were applied. No
session required discontinuation, and there were no adverse events. Data collection was
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feasible and there were no missing data. Satisfaction with the tDCS-telehealth
procedure was high and the patients were comfortable using the system.
Conclusion: At-home tDCS with telehealth support appears to be a feasible approach
for the management of symptom burden in patients with chronic illness. Further studies
to evaluate and optimize the protocol effectiveness for symptom-control outcomes are
warranted.
Keywords: non-invasive brain stimulation, transcranial direct current stimulation, patient-tailored protocol,
chronic illness, symptom management, home settings, at-home tDCS
INTRODUCTION
In the United States, at least 175 million people are chronically ill
(Centers for Medicare and Medicaid Services, 2012; Ortman et al.,
2014). Most are elderly and receive care in the ambulatory setting
or at home (Hasselman and Center for Health Care Strategies,
2013). Effective symptom management is essential but is often
challenged by the occurrence of multiple symptoms and the need
for polypharmacy, which may produce adverse effects in the
medically fragile. For many patients, the need for frequent visits
to a physician’s office presents additional challenges. Innovative
strategies for symptom management that could be provided at
home and reduce the reliance on drug therapy would represent
a significant advance in addressing the burden of illness among
seriously ill patients.
Transcranial direct current stimulation (tDCS) is a non-
invasive and non-pharmacological intervention that may address
multiple symptoms of chronic illness (Nitsche and Paulus, 2000;
Fregni et al., 2006a,b; Rigonatti et al., 2008; Valle et al., 2009; Loo
et al., 2012; Knotkova et al., 2014a,b). tDCS is delivered via a
battery-powered device with two or more electrodes that transfer
electrical current of low intensity (usually 1–2 mA) to the surface
of the head. The primary mechanism of tDCS is a subthreshold
modulation of neuronal resting membrane potential (Nitsche and
Paulus, 2000). If delivered for several minutes, tDCS can induce
neuroplasticity of glutamatergic synapses, resulting in enduring
alterations of neural excitability (Nitsche et al., 2003; Antal et al.,
2010; Monte-Silva et al., 2013). Recent evidence suggests that
tDCS interacts with various neurotransmitters in the brain, such
as dopamine, acetylcholine, serotonin and gamma-aminobutyric
acid (GABA; Nitsche et al., 2004a,b,c, 2006, 2009; Polania et al.,
2011; Stefani et al., 2012; Stagg et al., 2013). The neurophysiologic
effects of tDCS can be detected in cortical and subcortical
areas distant from the site of stimulation, and recent findings
suggest that tDCS can upregulate and downregulate functional
connectivity within complex brain networks, such as those that
are important for cognitive, motor, and pain processing or
mood modulation (Stagg et al., 2013). The scientific rationale
for tDCS studies in symptom management builds on findings
from neurophysiological and neuroimaging studies indicating
that the development and maintenance of symptoms frequently
occurring in various chronic illnesses are associated with changes
in cerebral networks and altered functional connectivity (e.g.,
Apkarian et al., 2013; Hemington et al., 2016). Earlier studies
suggest that reversal of these potentially maladaptive changes
in brain function is possible and can be associated with
an improvement of symptoms (Maihöfner et al., 2003, 2004;
Napadow et al., 2012; and others). Neuromodulation techniques,
such as tDCS, can induce enduring alterations of neural activity
and connectivity, and can be used to attempt reversal the
maladaptive neuroplastic changes occurring in chronic illness
(Lefaucheur, 2016; Stock et al., 2016; Woods et al., 2016).
Numerous randomized controlled trials suggest that tDCS
can relieve symptoms common in chronic illness, such as pain,
fatigue, sleep difficulties, or mood disturbance (Fregni et al.,
2006a,b; Roizenblatt et al., 2007; Boggio et al., 2008; Valle et al.,
2009; Loo et al., 2012; Brunoni et al., 2014; Ferrucci et al., 2014;
Saiote et al., 2014; Fagerlund et al., 2015; and others). Although
the extant evidence would support a trial of tDCS in chronically
ill patients with multiple poorly controlled symptoms, the access
to tDCS for those patients has been constrained. There are many
potential reasons for this observation, among which may be
the burden associated with the conventional tDCS approach,
which requires consecutive daily visits to an office for 1 or more
weeks. The development of a home-based tDCS intervention
suitable for the chronically ill with complex symptoms would
have the potential to expand access to this promising non-
pharmacological method.
We have developed a novel intervention that combines at-
home tDCS and telehealth support; we have adapted the tDCS
procedure and technology for easy home use by the chronically
ill, and developed instructional materials, a comprehensive
training plan, and a patient-tailored tDCS application protocol
that allows for dose-control, and enhanced adherence and safety
monitoring in remote. Here we describe the development of this
intervention and feasibility testing in four patients with advanced
chronic illness and multiple unrelieved symptoms.
MATERIALS AND METHODS
Development
The guiding principles for the development of the intervention
were low burden for the patient, strict dose control, and enhanced
monitoring for adherence and safety. To identify and adjust
potentially difficult steps in the tDCS application for patients
and their informal caregivers, analysis of the tDCS procedure
was performed. Possible solutions were presented to a group
of hospice and palliative care professionals in expert-feedback
sessions that included in total six experts (1M, 5F) whose
experience in hospice and palliative care averaged 24 years and
whose current positions were either managerial or clinical. After
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each expert provided consent, he or she was interviewed and
asked to provide specific feedback on suitability of the adjusted
tDCS procedure for patients and their informal caregivers and
on versions of lay-language training materials – an instructional
video and a step-by-step brochure.
The device for home-based tDCS was the “1X1 tDCS mini-
CT” device, model 1601 (Soterix Medical Inc., NY, United States),
with two 5 cm × 5 cm saline-soaked sponge electrodes. The
device included a safeguard for dose control, consisting of
electronic unlocking codes, that were provided to the patient or
caregiver prior to each tDCS treatment. The device also generated
an electronic post-treatment record that informed the tDCS
technician about completion, interruption, or restart of the tDCS
session.
The telehealth device paired with the tDCS unit was a
Samsung Galaxy touchscreen tablet 6.93′′ × 9.57′′. The tablet
contained educational and instructional materials for the patient
and informal caregiver and allowed secure videoconferencing
with the patient for remote assistance and adherence monitoring
by the tDCS technician.
Pilot to Assess Feasibility
To perform an initial evaluation of the feasibility of the at-home
tDCS-telehealth intervention, four patients were recruited
following referrals from MJHS Hospice and Palliative Care
personnel. Patients were required to be at least 18 years of age,
English-speaking, able to provide informed consent, have at least
one chronic illness, and to report moderate to severe distress from
one or more of the following symptoms: pain, fatigue, difficulties
concentrating, worrying, feeling sad, or feeling nervous, as self-
rated by the patient on the Condensed Memorial Symptom
Assessment Scale (CMSAS; below).
Patients were excluded if they had metal implants in the
head or in the neck; cancer affecting the head; history of
seizures or seizure disorder; unstable acute medical condition;
compromised integrity or sensitivity of the skin at or near
locations where electrodes would be placed; or if they used
another neurostimulation device.
Patients had an option to include their informal caregiver to
assist with the tDCS procedures. To co-participate, the caregivers
were required to be at least 18 years of age, able to follow
instructions in English, and to provide informed consent.
The at-home tDCS was applied in accordance with a
patient-tailored protocol (described in detail in section Results)
in two phases: 10 daily tDCS sessions on 10 consecutive days
were followed by as needed applications over 20 days, using
either the “DLPFC” montage or “M1-SO” electrode montage.
The montage selection was congruently informed by findings
from previous studies and patient’s report of most distressing
symptom(s) at screening. Patients were considered for the study
participation if they reported moderate to severe distress from
one or more of the following symptoms: worrying, feeling sad,
feeling nervous, difficulties concentrating, fatigue, or pain. Based
on findings from previous studies, each of these symptoms can
be addressed using the “DLPFC” montage with the anode on the
left hemisphere over the area corresponding with the F3 point
of the international 10–20 EEG system and the cathode over F4
(Valle et al., 2009; Brunoni et al., 2013; Saiote et al., 2014; Sandrini
et al., 2014; Glaser et al., 2016; Manenti et al., 2017; and others).
However, specifically for pain, the more common tDCS montage
is the “M1-SO” montage, with the anode over the area of the
motor cortex (C3 or C4 of the 10–20 EEG system) contralateral
to pain-affected side of the body in unilateral pain, or over C3
in bilateral pain, with the cathode over the supraorbital region
on the hemisphere contralateral to the anode placement (Fregni
et al., 2006a,b; Valle et al., 2009; Mori et al., 2010; Kim et al., 2013;
and others). In our study, the “M1-SO” montage was used if pain
was reported as dominating most distressing symptom.
Data Collection
Patients’ sociodemographic characteristics – age, race, marital
status, living status (lives alone, does not live alone), education
(high school ∼12 years of education; some college ∼13–15
years; undergraduate ∼16 years; graduate school ∼18+ years of
education), were recorded. Performance status was assessed with
the Karnofsky Performance Status scale (KPS) between 0 and
100, with anchor points 0 (death) and 100 (no complaints/no
evidence of disease) (Schag et al., 1984). Symptom distress was
assessed with the CMSAS, a validated 14-item questionnaire used
to evaluate the prevalence and distress associated with 11 physical
and 3 psychological symptoms (Chang et al., 2004). Prevalence
was indicated on a single item, which was checked if the symptom
was experienced during the indicated timeframe. Distress due
to each of the physical symptoms was measured on a Likert-
type scale, which asked “How much did the symptom bother or
distress you in the past 7 days?” and was graded using a 5-point
scale: 0 (no distress at all), 1 (a little bit), 2 (somewhat), 3 (quite a
bit), and 4 (very much). Distress due to each of the psychological
symptoms was measured on a 4-point scale that asked “How
frequently did the following symptom occur?” and was graded
1 (rarely), 2 (occasionally), 3 (frequently), 4 (almost constantly).
The scores for the Global Distress and its two subscales Physical
Symptom Distress and Psychological Symptom Distress were
calculated as the sum of the scores reported on corresponding
groups of physical and psychological symptoms. The assessment
was carried out at the baseline, at the end of the first ten
sessions, and again at the end of the twenty-day optional phase
involving up to ten additional applications. Patient satisfaction
with the tDCS system was determined from an 8-item user survey
administered after the last tDCS application.
The study was carried out in accordance with the
recommendations of the Handbook for Good Clinical Research
Practice, WHO, 2002. The procedures were approved by the
New England Independent Review Board (NEIRB), and all
participants provided written informed consent in accordance
with the Declaration of Helsinki.
RESULTS
Development of the Intervention
Adjustment of the tDCS Application Process
A step-by-step analysis of tDCS application process informed
by expert feedback identified major challenges associated with
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TABLE 1 | Analysis of the tDCS application process, with focus on potentially difficult steps in tDCS application for seriously ill patients and their informal caregivers; and
possible solutions.
Step Challenge Solution
Having all elements of the tDCS kit
ready
Misplacing supplies Supplies for one stimulation session enclosed in an individual
pouch; sufficient number of pouches included in the tDCS-kit
briefcase dispensed to patient at the initial visit; the tDCS-kit
briefcase labeled, with a note for proper storage.
Preparing electrodes Proper assembly of the electrode Cable insertion clearly depicted in the patient’s instructional
materials
Replicable saturation 5 ml syringes pre-filled with saline included in the tDCS kit
Electrode montage Determining the electrode position without the 10–20 EEG
measurements
Size-fitted headband allowing for accurate and replicable
electrode placement (Figure 1)
Securing the electrode on the head Size-fitted headband
Connecting electrode cables with
the device
No challenge (cables and inserts are color-coded) –
Preparing the device Identification of the keypad buttons Depicting the keypad and snapshot of the screen in the
patient’s instructional materials
Checking connection Understanding connection-quality grades Using lay-language words; avoiding alarming words, such as
“critical”
Performing corrective action if connection quality is
unacceptable
Training the patient in possible corrective actions
Starting the stimulation Using the start code obtained from tDCS technician Describing the procedure in lay language in the patient’s
instructional materials and depicting the snapshot of the screen
and the prompt for the start code
Ending the stimulation Obtaining/recording the end code generated by the device Describing the procedure in lay language in the patient’s
instructional materials and depicting an example of the
generated end-code
Clean up No challenge –
Batteries Changing/charging batteries as needed Depicting the process step-by-step in the patient’s instructional
materials
preparation of the electrodes and with the electrode montage
(Table 1).
To assure replicable saturation of the electrode sponges, saline
was pre-filed into 5 ml syringes that were included in the tDCS
kit dispensed to the patients. To achieve electrode montage
without the 10–20 EEG measurements, electrodes were placed in
a headband that held the electrodes in the desired position for the
stimulation over the area of the primary motor cortex (“M1-SO”
montage, Figure 1; Knotkova et al., 2017), or over the dorsolateral
prefrontal cortex (“DLPFC”; Seibt et al., 2015), based on reported
symptoms. The headband had a navigational mark that served as
reference point for proper positioning and was size-fitted to the
patient at the time of equipment dispense.
Patient-Tailored Protocol
The protocol included one home visit for consenting, eligibility
screening, initial tDCS tolerability test, and in-person initiation
of tDCS training. The training process (Figure 2) continued
using instructional materials preloaded on the telehealth tablet
(Figure 3) with remote assistance via videoconference as needed.
The training was concluded with the tDCS Competency test.
tDCS was applied in two phases; first, patients are encouraged
to apply 10 sessions, one 20-minute stimulation per day on 10
consecutive days. This build-up phase was followed by a fully
optional 20-day period, during which the patient could apply
tDCS as needed for up to ten additional sessions delivered once
or twice per day. The number of applications in the “as-needed”
regimen was guided by the patient judgment and the frequency
was determined by the patient without input from the study
personnel.
The protocol had seven specific elements that allowed for
tailoring (T) to the needs and preferences of the patient (Figure 4,
T1–T7), and six elements that supported monitoring for safety
and compliance with the protocol (C; Figure 4, C1–C6).
The elements for tailoring treatment included: (1) optional
inclusion of assisting informal caregiver; (2) broad inclusion
criteria that allow targeting of one or more of multiple symptoms;
(3) tailored stimulation intensity (default of 1.5 mA, but able
to be decreased to 1 mA for patients who perceive 1.5 mA
as unpleasant); (4) tailored tDCS training involving either the
patient or a co-participating informal caregiver, or both, and
mediated through instructional video, videoconference with
tDCS technician and/or a step-by-step brochure; (5) versatility
of remote assistance via a videoconference or by phone, with
frequency and mode of assistance determined by the patient’s
needs; (6) a recommended regimen during the first block of
stimulation (tDCS applications on consecutive days strongly
encouraged but not mandated); and (7) optional applications in
the second phase, potentially allowing twice daily stimulation.
The elements that supported safety and monitoring for the
adherence with the protocol (Figure 4, C1–C6) included the
following: (1) exclusion criteria that precluded tDCS initiation
in patients with metal implants in the head/face, history of
seizures or brain tumor, compromised skin integrity at the
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FIGURE 1 | tDCS headgear for the electrode M1-SO montage with the anode
over the area of the motor cortex and the cathode over the contralateral
supraorbital region. The headgear (A,B) does not require neuronavigational
measurements. The center point (blue arrow) supports accurate
self-placement by user. The headgear accommodates either conventional
saline-soaked electrodes (C) or snap-on pre-moisturized ones (D). Panel AB
is courtesy of HK. The person shown has given permission to publish this
picture.
electrode-placement area, or an inability to provide consent
or follow instructions; (2) initial tDCS tolerability test, which
excluded participants who could not tolerate 1 mA of stimulation;
(3) use of a competency test at the conclusion of training to
assure preparedness of the tDCS operator (patient or assisting
informal caregiver), and exclusion of patient if competency in
the application process could not be demonstrated within 1
week after initiation of training; (4) monitoring for compliance
with good practices in tDCS (including remote quality checks
to evaluate if procedures for the electrode preparation and
tDCS delivery were done properly and in accordance with
training materials); (5) comprehensive safety monitoring that
ensured that safety checks prior to and during stimulation were
completed (e.g., intact skin in the electrode area and absence
of adverse effects), and that stimulation be stopped if perceived
as painful; and (6) electronic dose control: the device was
electronically unlocked for each session at a pre-set dose and
provided an end-of-session code indicating whether stimulation
was completed, delivered without or with interruptions, or was
aborted.
Pilot to Assess Feasibility
Four patients were recruited for the initial feasibility assessment.
The patients’ characteristics are summarized in Table 2.
Patient 1 was a 52-year-old Hispanic male, single, but not
living alone, and not employed. He had advanced congenital
myasthenia gravis associated with quadriplegia and chronic
ventilator support. The patient experienced severe distress
from chronic pain of the neck, lower back, and right lower
limb for longer than 1 year. Other reported symptoms
Initial familiarization with the device
In-person training by tDCS technician 
at patient’s home
Quality checks
In-remote training with tDCS technician via 
videoconference
1. The stimulation pads are properly 
moisturized and clipped to the headband 
2. The headband is correctly positioned on the 
patient’s head
3. The device is prepared and turned ON 
4. Quality of contact is checked and adjusted 
if needed
5. Device is set, ready to be  activated with 
the code for the stimulation
Competency test
Practicing/Skill-building using instructional 
materials – brochure and video
FIGURE 2 | A step-by-step training plan to build patients’ and caregivers’
competency for tDCS applications.
included fatigue, insomnia, difficulty concentrating, nervousness,
worrying, feeling sad, lack of appetite, dry mouth, weight loss,
and constipation. Symptoms were poorly controlled despite
treatment with fentanyl and gabapentin. The patient was severely
disabled, with the KPS score of 30.
Patient 2 was a 44-year-old Hispanic female, single, but
not living alone, and not employed. She had a longstanding
indolent spinal tumor associated with back pain and depressed
mood (worrying, feeling sad), and reported severe distress
from each of these symptoms for longer than one year. Other
reported symptoms included lack of energy, lack of appetite, dry
mouth, feeling drowsy, constipation, nausea, difficulties sleeping,
and difficulties concentrating. Symptom-directed medications
included baclofen, hydromorphone, oxycodone-acetaminophen,
escitalopram, docusate, diphenhydramine, and pantoprazole
sodium. The patient had the KPS score of 80, able to carry on
normal activity with effort.
Patient 3 was a 58-year-old white female, married, and not
employed. She had post-traumatic plexopathy and chronic pain
in the left lower limb that caused moderate symptom distress
for more than 1 year. Other reported symptoms were difficulty
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FIGURE 3 | A snapshot of the tDCS instructional brochure for patients.
concentrating and feeling nervous. Pain was poorly controlled
despite hydromorphone. Her KPS was 90, able to carry on normal
activity.
Patient 4 was a 63-year-old Hispanic male, married, and not
employed. The patient had a history of stroke and associated left
leg and arm paralysis and chronic pain. The pain was adequately
controlled with gabapentin, but the patient experienced burden
due to psychological symptoms – worrying, feeling sad, and
feeling nervous for longer than three months. His KPS was 70,
able to care for himself, but not able to carry on normal activity
or do active work.
Patients #1 and #4 opted for an inclusion of informal caregiver
to assist with tDCS administration.
At the initial visit at the patient’s home, patients and co-
participating informal caregivers provided informed consent and
were screened. Initial familiarization with the device proceeded
without difficulties and patients received size-fitted headbands
for electrode placement for the following montages: the “M1-
SO” with anode on the left (Patient #1) or right (Patient #3);
and the “DLPFC” montage (Patients #2 and 4). All patients
underwent the initial acceptability test and found the intensity
of stimulation at 1.5 mA acceptable. Training proceeded without
difficulty and all designated tDCS operators (Patients #2 and 3
themselves and assisting caregivers for Patients #1 and #4), passed
the competency test and were allowed to proceed with tDCS
applications.
FIGURE 4 | Protocol for tDCS application by chronically ill patients at home.
The protocol includes 1 at-home visit and has specific elements that allow for
tailoring to the needs and preferences of the patient (T1–T7), as well as
elements that support safety and adherence monitoring (C1–C6).




1 2 3 4
Age 52 44 58 63
Race/ethnicity Hispanic Hispanic White Hispanic
Sex Male Female Female Male
Marital status Single Single Married Married
















Education in years 13–15 13–15 18+ 12
Karnofsky
performance status
30 80 90 70
In the first tDCS phase, all patients received 10 applications
on 10 consecutive days. In the second “as needed” phase, Patients
#1 and 3 did not opt for additional applications during the
subsequent period and Patients #2 and 4 received another 10
sessions, no more than one session per day. No adverse events
were reported.
Outcome data collection using the CMSAS was carried out
without problems. There were no missing data and the results
illustrate feasibility of tracking symptom scores. At the baseline,
Patients #1 and 2 had high Global Distress Score of 32.4
and 39.2, respectively; the score substantially declined to 9.6 and
14.0, respectively after 10 consecutive tDCS applications, and
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FIGURE 5 | Results of the tDCS satisfaction survey by the four patients and
two co-participating caregivers.
remained low, 4.0 and 11.0, respectively, at the end of the as
needed phase in which Patient #1 did not opt for any tDCS session
and Patient #2 received 10 additional applications. Patients #3
and 4 had the baseline Global Distress Score low, 8.6 and 8.0,
respectively, and no substantial change was noted in the course
of tDCS treatment; the score was 7.6 and 8.6, respectively, after
10 tDCS applications, and 11.6 and 10.0, respectively, after the
optional phase in which Patient #3 has not received any tDCS
application and Patient #4 opted for 10 sessions. These results do
not reflect efficacy given the small sample, lack of a comparator,
and varied number of tDCS applications; they do, however,
demonstrate the ability of symptom measurement to capture
different response profiles during home-based tDCS trials.
On the satisfaction survey (Figure 5), all four patients and
the two co-participating caregivers indicated “agreed/strongly
agreed” in response to statements “I find the use of tDCS
device easy,” “I was comfortable using the tDCS device,” and
“I was satisfied with the education and information I received
before using the device.” Five users agreed/strongly agreed with
statements “If I were offered this device and equipment in
the future I would use it again,” and “I was satisfied with the
overall experience of using the tDCS device,” four users would
recommend the device to others, and three users agreed/strongly
agreed with statement “With the help of the tDCS device I am
more confident managing the symptoms at home.”
DISCUSSION
We have developed a novel at-home tDCS intervention with
telehealth support and have demonstrated initial feasibility in
four patients with complex symptom control problems associated
with chronic illness. There were no difficulties with the initial
study visit at the patient’s home, training or patients’ acceptance
of the procedure. The adherence to the protocol was excellent; no
session required discontinuation, all patients received 10 tDCS
sessions as recommended in the initial phase and proceeded
to the as-needed phase. Data collection was without problems
and there were no missing data. Although a decrease of post-
tDCS CMSAS scores was noted in two patients, no conclusions
should be drawn from these findings as there was no control
comparison, the number of subjects was low, and the study was
not designed to evaluate efficacy of the procedure. Regardless,
the patients’ and caregivers’ satisfaction with the procedure was
high; they were satisfied with the training and were comfortable
using the device, indicating very good acceptability of the
intervention. Overall, our findings suggest that with proper
training and enhanced remote monitoring, tDCS application
in home-bound patients with multiple chronic symptoms is
possible.
The approach allows for tailoring the procedures to the
needs and preferences of the patient, as well as includes
elements for enhanced safety and adherence monitoring, low
burden, and ease of use. The instructional materials, training
procedures, and quality check enable patients and their informal
caregivers to develop skills necessary for tDCS application in
accordance with good practices. The frequent contact with a
tDCS technician via video-conference and telephone enables
remote assistance as needed and enhances safety and adherence
monitoring. Safety and adherence with the protocol are further
supported by technical features of the equipment, which includes
remote dose control, and simple easy-to-use headgear allows for
reliable electrode montage without performing the 10–20 EEG
measurements.
Importantly, this novel intervention comports with guidelines
for tDCS use in clinical patient-populations in home settings
(Charvet et al., 2015). The recommendations include: (1) training
of staff in tDCS treatment and supervision; (2) assessment of
the user’s capability to participate in tDCS remotely; (3) training
procedures and materials including assessments of the user
and/or caregiver; (4) simple and fail-safe electrode preparation
techniques and tDCS headgear; (5) strict dose control for each
session; (6) ongoing monitoring of compliance/adherence to the
protocol; (7) monitoring for treatment-emergent adverse effects;
and (8) guidelines for discontinuation of a session and/or study
participation (Charvet et al., 2015).
This novel non-pharmacological adjuvant tDCS-telehealth
intervention is well positioned to address the needs of seriously ill
patients in home settings and promote the national goal of more
effective community-based care. It can also support the efforts
to reduce the need for drug therapy, particularly in chronically
ill older patients. Recent surveys indicate that almost one-third
of Medicare beneficiaries take ≥5 prescribed medications, and
the polypharmacy is associated with higher risks for the patients
when possible adverse effects of drug therapy may compound the
risks associated with disease-related organ dysfunction (Centers
for Medicare and Medicaid Services, 2012; Hasselman and
Center for Health Care Strategies, 2013; Ortman et al., 2014).
Although existing evidence pertaining to the tDCS potential to
reduce medication intake stems from studies in postoperative
settings (Borckardt et al., 2011, 2013; Glaser et al., 2016), this
tDCS-telehealth intervention can facilitate future explorations of
this potential for the chronically ill in home settings.
Each component of this novel intervention, tDCS and
the telehealth support, has potential to substantially facilitate
symptom control. Randomized controlled studies (Boggio
et al., 2008; Hagenacker et al., 2014; Fagerlund et al., 2015;
Lefaucheur, 2016; and others) have shown that tDCS delivered in
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several sessions can reduce symptoms common in chronic illness,
such as pain, fatigue, sleeping difficulties, cognitive difficulties,
worrying, or depression, and can result in decreased demand
for symptom-directed medications (Borckardt et al., 2011, 2013;
Glaser et al., 2016), while telehealth support may help the
chronically ill get engaged in symptom monitoring, facilitate
access to information about symptom management, or facilitate
contact with the support team (Kearney et al., 2009; Kroenke
et al., 2010; Head et al., 2011; Johnston et al., 2012; Ruland et al.,
2013; and others). In the past decade, various telephone-based or
computer-based systems have been tested to enhance reporting
and monitoring symptoms in patients with serious illnesses,
such as cancer, in both urban and rural areas, and preliminary
results suggest high acceptance of this approach by patients
and families (Davis et al., 2007; Weaver et al., 2007; Grubaugh
et al., 2008; Kroenke et al., 2010; Head et al., 2011). Although
it is impossible to circumvent the physical and psychological
impact of chronic illness on patients and their families, telehealth
technology provides innovative remote ways toward improving
patient education, symptom assessment, communication and
outreach by the support team.
Further, the protocol for application of this at-home
tDCS-telehealth intervention can serve as a template or a generic
protocol for future tDCS studies or tDCS clinical applications in
the chronically ill. Various sets of outcome assessment tools can
be easily incorporated in the protocol and the number of tDCS
sessions in the two phases of tDCS applications can be adjusted as
well. The tDCS-telehealth intervention offers many opportunities
for further modification of the technology and the protocol to the
needs of various patient populations.
Overall, we aimed for the development and initial
feasibility testing of the novel tDCS-telehealth intervention for
home-bound chronically ill patients with multiple unrelieved
symptoms. The pilot study was not intended to investigate the
clinical efficacy of the intervention and no conclusions about the
efficacy should be drawn from the reported results. Further, due
to a low sample size, the findings on feasibility of the procedure
in the home-bound chronically ill are preliminary, and larger
studies are needed to further evaluate the intervention and to
determine/optimize the protocol efficacy and effectiveness for
symptom control outcomes.
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